サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1571947

気管支拡張薬の世界市場

Bronchodilators

出版日
ページ情報
英文 93 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
気管支拡張薬の世界市場
出版日: 2024年10月18日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 93 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

気管支拡張薬の世界市場は2030年までに450億米ドルに達する見込み

2023年に327億米ドルと推定される気管支拡張薬の世界市場は、分析期間2023～2030年にCAGR 4.7%で成長し、2030年には450億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである喘息適応症は、CAGR 5.4%を記録し、分析期間終了時には191億米ドルに達すると予測されます。慢性閉塞性肺疾患適応症セグメントの成長率は、分析期間中CAGR 4.5%と推定されます。

米国市場は88億米ドル、中国はCAGR 7.9％で成長予測

米国の気管支拡張薬市場は2023年に88億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR7.9%を牽引し、2030年までに97億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と3.9%と予測されています。欧州では、ドイツがCAGR 3.1%で成長すると予測されています。

世界の気管支拡張薬市場- 主要動向と促進要因のまとめ

なぜ気管支拡張薬は呼吸器疾患の管理に不可欠なのか？

気管支拡張薬は、喘息、慢性閉塞性肺疾患（COPD）、気管支炎など、様々な慢性・急性呼吸器疾患の管理に使用される重要な薬剤です。主な作用は、気管支の筋肉を弛緩させ、気道を広げ、気道抵抗を減少させることで、気流を改善し、息切れ、喘鳴、胸部圧迫感などの症状を緩和します。気管支拡張薬は、その作用機序から、β2作動薬、抗コリン薬、メチルキサンチン薬の3つに分類されます。サルブタモールやホルモテロールなどのβ2作動薬は最も広く使用されており、肺のβ2受容体を刺激して平滑筋を弛緩させることで作用します。イプラトロピウムやチオトロピウムなどの抗コリン薬は、副交感神経系を抑制して気管支収縮を防ぎ、気道拡張を促進します。テオフィリンを含むメチルキサンチン系薬剤は、治療指数が狭いため、現在ではあまり使用されないが、特定の複雑な症例では依然として役割を果たしています。これらの薬剤は、呼吸器疾患の重症度や性質に応じて、吸入、経口、静脈内などさまざまな経路で投与することができます。吸入は、薬剤を肺に直接投与するため、全身的な副作用を最小限に抑えながら迅速な緩和をもたらすことができ、依然として好ましい方法です。気管支拡張薬の臨床的有効性は、特定の患者のニーズに合わせることができることと相まって、呼吸器疾患の緊急および長期管理の両方において不可欠なものとなっており、患者のQOLを著しく向上させています。

新しい気管支拡張薬製剤はどのように治療パラダイムを変革しているのか？

気管支拡張薬の分野では、従来の治療法の限界に対処し、患者の予後を改善するために、新しい製剤やデリバリーシステムが開発され、過去10年間に大きな進歩を遂げてきました。最も注目すべき動向のひとつは、長期間の症状コントロールを提供し、頻繁な投与の必要性を減らす長時間作用型の気管支拡張薬へのシフトです。サルメテロールのような長時間作用性β2作動薬（LABA）やチオトロピウムのような長時間作用性ムスカリン拮抗薬（LAMA）は、COPDや中等症から重症の喘息の維持療法における基礎治療となっています。これらの薬剤は単独または吸入コルチコステロイドと併用することにより、持続的な気管支拡張作用を発揮し、増悪を抑制し、肺機能全体を改善します。もう一つの重要な発展は、複数のクラスの気管支拡張薬と抗炎症剤を一つのデバイスに組み込んだデュアルおよびトリプルコンビネーション吸入器の出現であり、これにより治療レジメンが簡素化され、患者のアドヒアランスが向上します。例えば、LABA、LAMA、吸入コルチコステロイドを組み合わせたトリプルコンビネーション吸入器は、気道管理への包括的なアプローチを提供し、重症COPDの管理で人気を集めています。さらに、デジタルセンサーを搭載したスマート吸入器などの革新的な送達技術は、薬剤の使用と服薬アドヒアランスのリアルタイムモニタリングを可能にすることで、患者ケアに変革をもたらしつつあります。これらのデバイスは、患者とヘルスケア提供者の双方にフィードバックを提供し、治療計画を最適化し、増悪のリスクを最小限に抑えるのに役立ちます。さらに、二機能性ムスカリン-β作動薬（MABA）のような新規作用機序を持つ新たな気管支拡張薬が臨床試験で検討されており、呼吸器疾患に対する治療手段のさらなる拡大が期待されています。

気管支拡張薬市場を形成する規制上および臨床上の考慮事項は何か？

気管支拡張剤市場は、規制方針、臨床ガイドライン、安全性の考慮事項が複雑に絡み合って形成されており、これらが一体となってこれらの治療法の承認、使用、商業的成功を決定しています。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関は、承認を与える前に、気管支拡張薬の有効性と安全性を実証する確固たる臨床エビデンスを要求します。臨床試験では、通常強制呼気量（FEV1）で測定される肺機能の改善だけでなく、症状頻度の減少、増悪、全体的なQOLの改善も示さなければならないです。安全性は主要な懸念事項であり、特に長時間作用型薬剤については、特定の患者集団における潜在的な心血管リスクと関連しています。その結果、規制機関は長期的な安全性の結果を監視するために、しばしば市販後調査やリスク管理戦略を義務付けています。さらに、Global Initiative for Chronic Obstructive Lung Disease（GOLD）やGlobal Initiative for Asthma（GINA）などの組織による臨床ガイドラインは、治療アルゴリズムを定義し、疾患の重症度や患者の特徴に基づいて特定の気管支拡張薬クラスを推奨する上で重要な役割を果たしています。これらのガイドラインは、新しいエビデンスや新たな治療法を反映するために定期的に更新され、ヘルスケア環境全体の処方パターンに影響を与えています。市場参入はさらに、償還政策や費用対効果分析の影響を受けるが、これらは国によって大きく異なります。旧来の気管支拡張薬のジェネリック医薬品のイントロダクションは市場競争を激化させ、価格を引き下げ、アクセスを拡大させているが、同時にブランド製品にとっては課題となっています。

気管支拡張薬市場成長の主な促進要因は？

気管支拡張薬市場の成長は、人口動態の動向、技術革新、ヘルスケアニーズの進化を反映したいくつかの主要要因によって牽引されています。主な要因の1つは、呼吸器疾患、特にCOPDと喘息の世界の有病率の上昇であり、これらは世界の罹患率と死亡率の主要原因の1つとなっています。人口の高齢化、都市化の進展、タバコの煙や工業排出ガスなどの環境汚染物質への曝露が、閉塞性気道疾患の効果的な管理を必要とする患者数の増加に寄与しています。また、治療効果を高め、治療レジメンを簡素化することで、患者のコンプライアンスを向上させ、入院を減らす併用療法へのシフトも大きな推進力となっています。持続的な症状コントロールを提供する1日1回投与の選択肢や合剤の開拓は、治療のアドヒアランスが課題である新興国市場で特に高く評価されています。さらに、呼吸作動装置やスマート吸入器などの吸入器設計における技術的進歩は、特に高齢者や小児患者にとって使いやすく効率的な送達システムに対する需要に応えています。個別化医療の台頭も市場に影響を及ぼしており、遺伝子、表現型、バイオマーカーのプロファイルに基づいて気管支拡張薬治療を調整することに注目が集まっています。さらに、遠隔医療や遠隔モニタリングソリューションの採用拡大により、リアルタイムの疾患管理と早期介入をサポートする包括的な呼吸器ケアモデルに気管支拡張薬を統合する新たな機会が生まれています。最後に、新興市場におけるヘルスケア支出の増加と呼吸器ケアへのアクセスの改善が、アジア太平洋やラテンアメリカなどの地域における気管支拡張剤市場の拡大を促進しています。これらの要因が相まって、世界の気管支拡張剤市場の成長を後押しし、呼吸器疾患の管理における気管支拡張剤の継続的な進化と関連性を確実なものにしています。

調査対象企業の例（全42件）

  • Ache Laboratorios Farmaceuticos
  • Aquinox Pharmaceuticals
  • AstraZeneca
  • BioMarck Pharmaceuticals
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Innoviva
  • MediciNova
  • Merck & Co., Inc.
  • Novartis Ag

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP17539

Global Bronchodilators Market to Reach US$45.0 Billion by 2030

The global market for Bronchodilators estimated at US$32.7 Billion in the year 2023, is expected to reach US$45.0 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2023-2030. Asthma Indication, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$19.1 Billion by the end of the analysis period. Growth in the Chronic Obstructive Pulmonary Disease Indication segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.8 Billion While China is Forecast to Grow at 7.9% CAGR

The Bronchodilators market in the U.S. is estimated at US$8.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Bronchodilators Market - Key Trends and Drivers Summarized

Why Are Bronchodilators Essential in the Management of Respiratory Disorders?

Bronchodilators are vital medications used in the management of a range of chronic and acute respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. Their primary function is to relax the bronchial muscles, widen the airways, and reduce airway resistance, thereby improving airflow and alleviating symptoms like shortness of breath, wheezing, and chest tightness. Bronchodilators are classified into three main categories based on their mechanism of action: beta-2 agonists, anticholinergics, and methylxanthines. Beta-2 agonists, such as salbutamol and formoterol, are among the most widely used and work by stimulating the beta-2 receptors in the lungs, leading to smooth muscle relaxation. Anticholinergics, such as ipratropium and tiotropium, inhibit the parasympathetic nervous system, preventing bronchoconstriction and promoting airway dilation. Methylxanthines, including theophylline, are less commonly used today due to their narrow therapeutic index but still play a role in certain complex cases. These agents can be administered through various routes, including inhalation, oral, and intravenous forms, depending on the severity and nature of the respiratory condition. Inhalation remains the preferred method as it delivers the medication directly to the lungs, providing rapid relief with minimal systemic side effects. The clinical effectiveness of bronchodilators, combined with their ability to be tailored to specific patient needs, makes them indispensable in both emergency and long-term management of respiratory diseases, significantly enhancing patient quality of life.

How Are New Bronchodilator Formulations Transforming Treatment Paradigms?

The field of bronchodilators has witnessed significant advancements over the past decade, with new formulations and delivery systems being developed to address the limitations of traditional therapies and improve patient outcomes. One of the most notable trends is the shift towards long-acting bronchodilators, which provide prolonged symptom control and reduce the need for frequent dosing. Long-acting beta-2 agonists (LABAs) like salmeterol and long-acting muscarinic antagonists (LAMAs) such as tiotropium have become foundational treatments in the maintenance therapy of COPD and moderate to severe asthma. These agents, when used alone or in combination with inhaled corticosteroids, provide sustained bronchodilation, reduce exacerbations, and improve overall lung function. Another significant development is the advent of dual and triple combination inhalers that incorporate multiple classes of bronchodilators and anti-inflammatory agents in a single device, simplifying treatment regimens and enhancing patient adherence. For example, triple-combination inhalers that combine a LABA, a LAMA, and an inhaled corticosteroid are gaining traction in the management of severe COPD, offering a comprehensive approach to airway management. Additionally, innovative delivery technologies, such as smart inhalers equipped with digital sensors, are transforming patient care by enabling real-time monitoring of medication use and adherence. These devices can provide feedback to both patients and healthcare providers, helping to optimize treatment plans and minimize the risk of exacerbations. Moreover, emerging bronchodilators with novel mechanisms of action, such as bifunctional muscarinic-beta agonists (MABAs), are being explored in clinical trials, promising to further expand the therapeutic arsenal for respiratory conditions.

What Are the Regulatory and Clinical Considerations Shaping the Bronchodilator Market?

The bronchodilator market is shaped by a complex interplay of regulatory policies, clinical guidelines, and safety considerations, which together determine the approval, usage, and commercial success of these therapies. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require robust clinical evidence demonstrating the efficacy and safety of bronchodilators before granting approval. Clinical trials must show not only improvements in lung function, typically measured by forced expiratory volume (FEV1), but also reductions in symptom frequency, exacerbations, and overall quality of life improvements. Safety is a major concern, particularly for long-acting agents, which have been associated with potential cardiovascular risks in certain patient populations. As a result, regulatory bodies often mandate post-marketing surveillance and risk management strategies to monitor long-term safety outcomes. Additionally, clinical guidelines from organizations like the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Initiative for Asthma (GINA) play a crucial role in defining treatment algorithms and recommending specific bronchodilator classes based on disease severity and patient characteristics. These guidelines are updated regularly to reflect new evidence and emerging therapies, influencing prescribing patterns across healthcare settings. Market access is further influenced by reimbursement policies and cost-effectiveness analyses, which vary significantly between countries. The introduction of generic versions of older bronchodilators has increased market competition, driving down prices and expanding access, but also creating challenges for branded products.

What Are the Key Drivers Behind the Growth of the Bronchodilator Market?

The growth in the bronchodilator market is driven by several key factors that reflect a confluence of demographic trends, technological innovations, and evolving healthcare needs. One of the primary drivers is the rising global prevalence of respiratory diseases, particularly COPD and asthma, which are among the leading causes of morbidity and mortality worldwide. Aging populations, increased urbanization, and exposure to environmental pollutants such as tobacco smoke and industrial emissions have contributed to a growing patient pool requiring effective management of obstructive airway diseases. Another significant driver is the shift towards combination therapies that offer enhanced therapeutic outcomes and simplify treatment regimens, thereby improving patient compliance and reducing hospitalizations. The development of once-daily dosing options and fixed-dose combinations, which provide sustained symptom control, has been particularly well-received in markets where treatment adherence is a challenge. Moreover, technological advancements in inhaler design, such as breath-actuated devices and smart inhalers, are meeting the demand for user-friendly and efficient delivery systems, especially for elderly and pediatric patients. The rise of personalized medicine is also influencing the market, with a growing focus on tailoring bronchodilator therapies based on genetic, phenotypic, and biomarker profiles, leading to more precise and individualized treatments. Additionally, the expanding adoption of telemedicine and remote monitoring solutions is creating new opportunities for integrating bronchodilators into comprehensive respiratory care models that support real-time disease management and early intervention. Finally, increased healthcare spending in emerging markets, coupled with improved access to respiratory care, is driving the expansion of the bronchodilator market in regions like Asia-Pacific and Latin America. Together, these factors are propelling the growth of the global bronchodilator market, ensuring its continued evolution and relevance in the management of respiratory diseases.

Select Competitors (Total 42 Featured) -

  • Ache Laboratorios Farmaceuticos
  • Aquinox Pharmaceuticals
  • AstraZeneca
  • BioMarck Pharmaceuticals
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Innoviva
  • MediciNova
  • Merck & Co., Inc.
  • Novartis Ag

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Bronchodilators - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Respiratory Diseases Drives Growth in the Bronchodilators Market
    • Here's How Increasing Incidence of Asthma and COPD Strengthens Business Case for Bronchodilator Therapies
    • Growing Demand for Long-Acting Bronchodilators Expands Addressable Market Opportunity in Chronic Respiratory Disease Management
    • Shift Towards Combination Inhalers Spurs Growth for Dual and Triple Therapy Bronchodilator Products
    • Rising Adoption of Bronchodilators in Pediatric Care Propels Demand for Child-Friendly Dosage Forms and Delivery Devices
    • Here's the Story: How Advancements in Inhaler Devices Enhance Market Potential for Innovative Bronchodilator Delivery Systems
    • Rising Preference for Portable and Discreet Inhalation Devices Throws the Spotlight On Smart Inhalers and Wearable Nebulizers
    • Here's How Rising Environmental Pollution Accelerates Demand for Bronchodilators in Managing Pollution-Induced Airway Conditions
    • Growing Utilization of Bronchodilators in Acute and Emergency Care Boosts Market Growth for Short-Acting Bronchodilator Formulations
    • Increasing Awareness and Early Diagnosis of Respiratory Conditions Strengthens Market Position of Bronchodilators in Preventative Care
    • Rising Adoption of Bronchodilators in Smoking Cessation Programs Enhances Market Potential in Pulmonary Rehabilitation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bronchodilators Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Phosphodiesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Sympathomimetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Sympathomimetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Sympathomimetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • JAPAN
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • CHINA
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • EUROPE
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Bronchodilators by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • FRANCE
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • GERMANY
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Bronchodilators by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • INDIA
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Bronchodilators by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Bronchodilators by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030
  • AFRICA
    • Bronchodilators Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Bronchodilators by Indication - Asthma, Chronic Obstructive Pulmonary Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Bronchodilators by Indication - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Bronchodilators by Drug Type - Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Bronchodilators by Drug Type - Percentage Breakdown of Value Sales for Anticholinergics, Combination Drugs, Phosphodiesterase Inhibitors and Sympathomimetics for the Years 2014, 2024 & 2030

IV. COMPETITION